The recruitment of transcriptional cofactors by sequence-specific transcription factors challenges the basis of high affinity and selective interactions. Extending previous studies that the N-terminal activation domain (AD) of ETV5 interacts with Mediator subunit 25 (MED25), we establish that similar, aromatic-rich motifs located both in the AD and in the DNA-binding domain (DBD) of the related ETS factor ETV4 interact with MED25. These ETV4 regions bind MED25 independently, display distinct kinetics, and combine to contribute to a high-affinity interaction of full-length ETV4 with MED25. Within the ETS family, high-affinity interactions with MED25 are specific for the ETV1/4/5 subfamily as other ETS factors display weaker or no detectable binding. The AD binds to a single site on MED25 and the DBD interacts with three MED25 sites, allowing for simultaneous binding of both domains in full-length ETV4. MED25 also stimulates the in vitro DNA binding activity of ETV4 by relieving autoinhibition. ETV1/4/5 factors are often overexpressed in prostate cancer and genome-wide studies in a prostate cancer cell line indicate that ETV4 and MED25 occupy enhancers that are enriched for ETS-binding sequences and are both functionally important for the transcription of genes regulated by these enhancers. AP1-binding sequences were observed in MED25-occupied regions and JUN/FOS also contact MED25; FOS strongly binds to the same MED25 site as ETV4 AD and JUN interacts with the other two MED25 sites. In summary, we describe features of the multivalent ETV4-and AP1-MED25 interactions, thereby implicating these factors in the recruitment of MED25 to transcriptional control elements. factors could use an additional MED25-binding site, outside of the N-terminal AD, to interact with MED25. Such a domain, if it functioned in the absence of the AD, might explain the retained transcriptional activity of the oncogenic ETV1/ETV4/ETV5 truncations.
Introduction
The activation domains (ADs) of sequence specific DNA-binding transcription factors interact with general transcription factors, coactivators, and chromatin remodelers, in order to regulate the location and activity of RNA polymerase II (Pol II) [1] . These interactions are important for the foundation of transcriptional programs that regulate development and establish cell-type identity [2] ; as such, components of these interactions are commonly mutated in human disease [3, 4] . Acidic ADs, originally noted for an enrichment of negatively-charged and non-polar residues [5, 6] , have an alternating pattern of negatively-charged/nonpolar and bulky hydrophobic/aromatic residues. Although usually disordered in isolation, ADs often become more helical when interacting with cofactors [7] [8] [9] [10] . These sequence and structural characteristics are presumably the foundation of the ability of a single AD to interact with multiple partners as a flexible hydrophobic/aromatic interface that can be presented differently to diverse proteins [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . However, higher affinity for a particular factor, and thus specificity, can be accomplished through the use of multiple ADs [21] [22] [23] [24] . ETV1, ETV4, and ETV5 form a subgroup within the ETS family of transcription factors, sharing high sequence conservation both within and beyond the DNA-binding domain (DBD). This subgroup is aberrantly overexpressed in a subset of prostate cancers [25] [26] [27] , and promotes PI3-kinase and RAS signaling pathways resulting in an aggressive and metastatic disease phenotype [28, 29] . Previously it was demonstrated that the N-terminal AD of ETV5 binds to the activator interacting domain (ACID) of Mediator subunit 25 (MED25) [7, 30] . However, ~ 10% of prostate cancers frequently harbor truncations of ETV1, ETV4, or ETV5 that lack this AD due to chromosomal rearrangements [31, 32] . This suggests that the AD is dispensable for the function of these factors in prostate cancer. Therefore, we hypothesized that ETV1/4/5 subfamily (AD) and the DNA-binding domain (DBD), bound the activator interacting domain (ACID) of MED25 via a similar motif (ΩxxxΩΦ or Φ Ω xxxΩ, where Ω is an aromatic residue, Φ is a hydrophobic residue, and x is any residue). MED25 activated the DNA binding of ETV4 by relieving a previously described autoinhibition mechanism. Full-length ETV4, bearing both regions, had higher affinity for MED25 than either domain alone. Furthermore, the kinetics of association and dissociation by each domain differed, suggesting a complex binding reaction when both are present. NMR spectroscopy, mutational studies, and protein-docking modeling provided evidence that the AD and DBD bound to the same site on MED25 ACID. However, the DBD also interacted with two additional, distinct sites on MED25, such that simultaneous occupancy was possible in spite of overlapping contact surfaces. We provided in vivo evidence for the importance of this interaction as MED25 and ETV4 occupancies were highly overlapping genome-wide, and there was a significant overlap in genes whose expression was affected by depletion of either factor.
MED25-occupied regions were enriched for ETS and AP1 binding sequences, and JUN/FOS heterodimers also contacted MED25 through a similar mechanism as ETV4.
Therefore, we propose that both ETV4 and AP1 transcription factors use multivalent interactions to recruit MED25 to gene regulatory regions and promote the stable assembly of transcriptional machinery.
Results

High-affinity interaction with MED25 is specific to the ETV1/4/5 subfamily of ETS factors
The interactions between MED25 ACID (residues 391-553) and several ETS transcription factors were measured by biolayer interferometry in which one species is attached to a substrate and solution binding of an analyte is monitored (Fig. 1a,b ).
Testing single concentrations of these full-length ETS factors, we observed a range of interaction strengths with MED25. ETV1 and ETV4 at 50 nM were sufficient for interaction with MED25, whereas, tenfold more ETS1 and SPDEF (500 nM) were required. No interaction with MED25 was detected with 500 nM of EHF, ERG, or ETV6.
We measured the relative strength of ETS factors binding to MED25 more accurately by determining the equilibrium dissociation constants (K D ) from kinetic rate constants (k a and k d ) ( Fig. 1c, Fig. S1a ,b, and Table S1 ). Interestingly, for all ETS factors the interaction data better fit a model assuming two ETS proteins binding to MED25, rather than a one-to-one interaction (Fig. S1c ). As other experimental approaches, discussed below, also support a multivalent ETV4-MED25 interaction, we report values calculated using the two-to-one model. ETV4, with K D values of 7 ± 3 and 28 ± 7 nM for the two interactions with MED25, and ETV1 (16 ± 5 and 21 ± 2 nM) bound to MED25 with 20-to 50-fold higher affinity compared to SPDEF (320 ± 90 and 5,000 ± 2,000 nM) ( Fig. 1c ).
Therefore, we conclude that high-affinity interaction with MED25 is specific to the ETV1/4/5 subfamily of ETS transcription factors.
Two distinct regions of ETV4 bind to MED25
We next sought to investigate the molecular basis of selectivity for high-affinity interaction between the ETV1/4/5 subfamily and MED25 ACID. Using ETV4 as a model for this subfamily, we interrogated the interaction between different fragments of ETV4 and MED25 with biolayer interferometry (Fig. 2a ). The N-terminal AD, ETV4 43-84 , bound to MED25 in a one-to-one manner with a K D of 700 ± 100 nM ( Fig. 2b,d and Table S1 ).
This value is comparable to previous measurements of the interaction between the conserved AD of ETV5 and MED25 by fluorescence polarization (580 ± 20 nM) and by isothermal calorimetry (540 ± 40 nM) ( Fig. S2) [7, 30] . As the AD bound MED25 with an approximately hundred-fold weaker affinity than full-length ETV4, we surmised that additional regions within ETV4 also contribute to the interaction with MED25. Indeed, ETV4 165-484 , which lacks the N-terminal AD, also bound to MED25 and used a two-to-one interaction mode reminiscent of full-length ETV4 (350 ± 80 and 2,200 ± 500 nM) ( Fig.   2c ,d). Testing of additional ETV4 fragments revealed that the minimal AD, ETV4 , and a broader N-terminal fragment, ETV4 1-164 , were equivalent in binding to MED25 (Fig. 2d ).
Likewise, ETV4 , which corresponds to the ETS domain and an additional α -helix H4 that is specific to the ETV1/4/5 subfamily, interacted with MED25 with similar affinity to that of ETV4 . Therefore, we conclude that the N-terminal AD and the C-terminal DBD contribute to the high-affinity binding of full-length ETV4 with MED25.
Interestingly, the kinetics of the ETV4 AD and DBD interactions with MED25
were noticeably different. The AD-MED25 interaction had relatively high association and dissociation rate constants (k a and k d , respectively), reflecting the faster association and dissociation for this interaction ( Fig. 2b and Table S1 ). In contrast, the DBD-MED25 interaction had relatively low k a and k d values indicating slower association and dissociation ( Fig. 2c and Table S1 ). These data suggest that the high affinity interaction between ETV4 and MED25 could be due to combining the fast association mechanism and the slow dissociation mechanism used by the AD and DBD, respectively.
Interaction between MED25 and ETV4 DBD: molecular interface and influence on
DNA binding
Previous studies provided structural characterization of the interaction between the ETV5 AD and MED25. Notably, the predominantly disordered AD becomes more helical in the MED25-bound state and phenylalanine and tryptophan residues in the AD are critical for this interaction [7, 30] . Based on the robust sequence conservation between the ADs of ETV1, ETV4, and ETV5 ( Fig. S2 ), we surmised that the ETV4 AD would interact with MED25 in a conserved fashion. Indeed, the introduction of Phe54Ala, Phe60Ala, or Trp64Ala mutations into ETV4 significantly disrupted interaction with MED25 ( Fig. S3a,b ). Therefore, we focused on characterizing residues that are important for the newly discovered interaction between the DBD of ETV4 and MED25.
NMR spectroscopy was used to investigate the MED25-interface of the ETV4 DBD. We compared the 15 N-HSQC spectra for 15 N-labeled ETV4 DBD [54] with or without unlabeled MED25 ACID ( Fig. S4a ). MED25 most strongly perturbed the signals from residues (Glu425 and Ser429) within α -helix H4 of ETV4 ( Fig. 3a and Fig. S4b ,c).
Additionally, signals from residues within H1, H3, and the β -sheet were perturbed. Based on the specificity of the ETV1/4/5 subfamily for high-affinity interactions with MED25, we focused on residues near the β -sheet and in H4. Surface-exposed residues on the β strands, as well as residues in loops flanking the β -strands, are poorly conserved among all ETS factors ( Fig. S2 ). Likewise, the sequence and secondary structure of H4 is not binding greater than tenfold. Ser429 occurs within a motif (LFSLAF) on H4 that is reminiscent of the N-terminal AD (FQETWL). This portion of the AD is critical for interaction with MED25 ( Fig. S3a ) and the conserved sequence in ETV5 becomes more helical when interacting with MED25 ( Fig. S2 ) [7] . By analogy to the AD, we reasoned that the surface-exposed phenylalanines in H4 might also be important for interaction with MED25. Indeed, mutation of both Phe428 and Phe432 to alanine resulted in an approximately thirty-fold disruption of MED25 binding (Fig. S3a,c) . These results suggest that a broad interface, including critical phenylalanines from α -helix H4 as well as residues from the β -strand of the ETS domain, contributes to the interaction of the DBD with MED25. Helix H4, by itself, resembles the AD suggesting that the AD and DBD of ETV4 bind MED25 through a similar motif ( Fig. 3c ). However, the contribution of additional residues outside of H4 suggests that the DBD uses a broader interface for interaction with MED25.
We previously demonstrated that α -helix H4 inhibits the DNA binding of the ETS domain of ETV4 [54] . Leu430 on the interior face of H4 is critical for this autoinhibition and interacts with conserved hydrophobic residues of the ETS domain. Hence, we questioned whether MED25 binding to the exterior face of H4 would affect DNA binding.
Using an electrophoretic mobility shift assay (EMSA), we observed that the addition of MED25 to the equilibrium DNA binding reaction resulted in a slower migrating band on the EMSA gel, which we propose to be a MED25-ETV4-DNA ternary complex ( Fig. 4a ).
As a control, equivalent amounts of MED25 did not interact with the EHF-DNA complex.
The presence of MED25 increased the affinity (K D ) of ETV4 for DNA approximately twofold ( Fig. 4b ). This matches the two-fold magnitude of DNA-binding autoinhibition that was previously attributed to H4 [54] . Mutation of the MED25-interaction site on H4 (Phe428Ala/Phe428Ala) or of the ETS domain-interaction site on H4 (Leu430Ala) both abrogated the activation of DNA binding by MED25 ( Fig. 4b ). We conclude that the interaction between MED25 and α -helix H4 activates the DNA binding of ETV4.
ETV4 AD and DBD interactions with MED25: single-site versus multisite binding
Having determined that the AD and DBD use similar motifs to interact with MED25, we next wanted to explore the AD and DBD binding sites on MED25. We utilized assigned 15 N-HSQC spectra and the tertiary structure of the ACID domain of MED25 that were previously reported [9, 10] . The ACID domain is a seven-stranded β -barrel with three peripheral α -helices ( Fig. 5a ). 15 N-labeled MED25 ACID was titrated with either the AD or the DBD of ETV4 ( Fig. S5a,b ). The addition of the AD resulted in robust and widespread changes in the 15 N-HSQC spectra of MED25 ACID ( Fig. S5c,e ).
Several amide 1 N H -15 N peaks displayed progressive chemical shift changes indicative of fast exchange behavior. We observed substantial line broadening, even at the lowest titration point, as has also been observed in MED25 ACID interactions with other activation domains [7, 9, 10] . Comparatively, the addition of ETV4 DBD resulted in more subtle changes in the spectra of MED25 ACID (Fig. S5d ,f). Amide signals showed relatively smaller chemical shift changes and line broadening was more gradual as DBD was added at 0.2:1, 0.5:1, and 1.2:1 molar ratios. Although exhibiting different effects upon AD and DBD titration, we interpreted the changes in the MED25 ACID 15 N-HSQC spectra as evidence for interaction with both of these ETV4 fragments.
We mapped the MED25 residues that exhibited amide peak intensity changes from both ETV4 titrations onto the structure of MED25 ACID ( Fig. 5 and Fig. S5e ,f). The AD most strongly perturbed residues that clustered in a single site formed by β -strands S3, S5, and α -helix H3, which we will term Site 1. The DBD influenced residues within Site 1 as well, but also at two different sites on additional faces of MED25 formed by S4, S7, and H1 (Site 2), and by S2, S4, and H2 (Site 3), respectively. These multiple sites all have concave grooves that are suitable for interaction with an α -helix, such as that formed by the AD or H4 of ETV4 ( Fig. S6 ). Hydrophobic and uncharged polar residues form the floor of these grooves with positively charged residues lining the perimeter.
While the AD appears to most strongly interact with Site 1 on MED25, we propose two possibilities to explain the absence of clustering for amide signal changes upon DBD titration to a single MED25 site. One possibility is that the DBD may alternately interact with multiple sites on different faces of MED25 ACID, thereby forming a "fuzzy" binding interface [8, 12] . Alternatively, the DBD may interact with a single site on MED25 and have significant through-molecule effects that influence other surfaces of MED25 without direct interaction. We next pursued further biochemical and structural characterization in an attempt to distinguish between these two models.
Mutagenesis was used to further investigate the binding of MED25 and ETV4.
Using MED25 residues implicated from the NMR experiments as a starting point, we focused on those that had surface-exposed side chains. Residues from the concave groove floors, and surrounding positively charged residues, of all three MED25 ACID sites were mutated. Based on the importance of aromatic residues in the AD and DBD for binding to MED25 ( Fig. 3a ), most residues were mutated to glutamate as we surmised that a negative charge would successfully disrupt any π -cation or hydrophobic interactions. The strongest mutants for both the AD (Gln451Glu) and DBD (Lys422Glu, Arg509Glu, Arg538Glu, and Lys545Glu) were located at Site 1 on MED25, suggesting that this may be the preferred binding site for either of these ETV4 fragments in isolation ( Fig. 6 , Fig. S7 , and Table S2 ). Interestingly, the mutations that disrupt AD binding cluster near the center of the groove in Site 1, whereas, the mutations that preferentially affect DBD binding are more spread out on Site 1. This suggests a broader surface at Site 1 is used for DBD binding, mirroring the broad surface on the DBD that is used for MED25 binding (Fig. 3a,b ). Although some mutations in MED25 Site 2 and Site 3 also disrupted AD binding, all MED25 mutations at these sites (Gln430Glu, Arg466Glu, His474Glu, Tyr487Ser, Leu514Glu, Lys518Ala/Lys519Ala/Lys520Ala, Ile521Glu, and Met523Glu) more strongly, or only, affected DBD binding ( Fig. 6 and Table S2 ). The spacing of the DBD-specific mutations at MED25 Sites 2 and 3 were also suggestive of a broad interface being important for interaction with the DBD at each of these sites.
Therefore, we interpret the importance of several surface-exposed residues at three distinct sites on MED25 ACID to support multiple MED25 binding sites for ETV4 DBD.
We used a protein-docking program, ZDOCK, to predict the structures of the AD-MED25 and DBD-MED25 bound complexes. ZDOCK uses complementary shape to analyze all possible binding modes between two proteins [55] . In addition to the structures for MED25 [9] and ETV4 DBD [56] , we generated an α -helical model of the AD for input into the protein-docking program. Based on the mutational data for ETV4, we restrained the predictions to include Phe60 and Trp64 of the AD, and Phe428 and Phe432 of the DBD in the interface for each of these respective interactions. We also restrained the AD-MED25 prediction to include MED25 Gln451 because NMR clearly localized AD binding to Site 1 on MED25 and the Gln451Glu was the single strongest mutant for AD binding. No MED25 residues were required to be involved in the DBD-MED25 modeling due to the broad localization of both the NMR spectral perturbations of amides, and the mutational effects on DBD binding, to multiple faces of MED25. The top ten predictions for the AD-MED25 interaction are very similar with the AD clustering in MED25 Site 1 (Fig. 7a ). The top ten DBD-MED25 predictions included the DBD binding to each of the three MED25 sites that were identified from NMR spectroscopy and mutational analysis, even though this information was not used to inform the predictions ( Fig. 7b ). In addition to α -helix H4, residues from H1 and the loops between β -strands on the DBD also contact MED25 in many of the predictions, thereby contributing to a broader interface with MED25. In summary, NMR spectroscopy, mutational analysis, and protein-docking predictions support multiple DBD binding sites on MED25 ACID.
ETV4 and MED25 share transcriptional targets in prostate cancer cells
Given the strong interaction between MED25 and ETV4, as well as the (Table S3 ). The vast majority of the enriched regions for each dataset mapped greater than 5,000 base pairs (bp) from defined transcriptional start sites, with almost half lying greater than 50,000 bp away, suggesting robust binding to distal enhancer elements ( Fig. S8a,b ). Intersection of the two datasets demonstrated a striking high degree of overlap; ~75% of the ETV4 peaks were in the MED25 dataset ( Fig. 8a,b and Table S3 ). We observed high enrichment of ETS binding motifs at the overlapping sites; the ETS binding site (CAGGAA) was the top overrepresented motif in the shared peaks and second top hit for all MED25 peaks after the AP1 binding sequence ( Fig. 8c and Fig. S8c ). We compared the frequency of the ETS binding motif between the shared peaks and a size-equivalent, randomly generated set of genomic sequences. Of the 611 ETV4-MED25 shared peaks, 223 had at least one C(C/A)GGAA sequence in their central 100 bp core; whereas, only 44 regions of a control dataset had the motif ( Fig. 8c and Table S3 ). Furthermore, only two of the 44 regions in the control dataset had multiple occurrences of the motif, while 50 of the 223 shared peaks had two or more ETS motifs. Several targets were confirmed by qPCR to validate the ChIPseq data and verify that these represent overlapping binding regions ( Fig. 8d and Fig. S8b ).
To test the functional relevance of this genomic occupancy, we sought to identify genes whose transcription was dependent on both MED25 and ETV4. We performed shRNA-mediated knockdown of endogenous MED25 and ETV4 in the PC3 cell line followed by RNAseq. Of the 153 and 57 genes down regulated by MED25 and ETV4 knockdown, respectively, 18% were in common (Table S5 ). Focusing on these common genes, 70% were associated with potential regulatory elements occupied by both ETV4
and MED25 (Fig. S8b ). The occupancies of putative regulatory elements for five genes (ANK2, CDK14, HEY1, IGF2BP1, and SDC1) were confirmed by qPCR of DNA in the peak region ( Fig. 8d and Fig. S8b ). Consistent with RNAseq results, all five of these genes were down-regulated in PC3 cells expressing either MED25 or ETV4 shRNA construct as assessed by RT-qPCR ( Fig. 8e ). From these findings we propose that MED25 and ETV4 interact at genomic sites and work together to regulate the transcription of ETV4 target genes.
JUN/FOS also binds to multiple sites on MED25
We were intrigued by the strong enrichment of AP1 binding sequences in our MED25 ChIP-seq dataset ( Fig. S8c) , as a MED25-AP1 interaction had not been previously reported. Using a published JUND ChIP-seq dataset from PC3 cells [57] , we found a 29% overlap in MED25-and JUND-occupied regions (Table S3 ). Furthermore, JUN and FOS also had one and two of the MED25-interacting motifs (ΩxxxΩΦ), respectively, occurring within previously annotated activation domains ( Fig. S9 ) [58, 59] .
To investigate this potential interaction, we used full-length JUN and FOS to prepare the differences in kinetic rates for these interactions. We hypothesize that the flexible AD interface associates rapidly with MED25 but also dissociates quickly due to the lack of supporting interactions; whereas, the broader DBD interface orients more slowly during association and forms a more stable interaction with MED25 that dissociates more slowly.
Biochemical results from biolayer interferometry binding studies as well as structural insight from NMR spectroscopy and protein-docking predictions indicate that the DBD interacts with three distinct sites on MED25, and the AD interacts with only one of these sites. These three MED25 sites are relatively similar in overall appearance;
hydrophobic and non-polar residues form the bottom of concave grooves with positively charged residues lining the perimeter. We speculate that the difference in single-site versus multisite binding for the AD-and DBD-MED25 interactions, respectively, reflects the different binding interfaces. For the AD, the exact spatial and chemical nature of the binding groove on MED25 Site 1 is critical for binding because this is the only point of contact. In contrast, the specifics of the MED25 binding grooves for binding to H4, at all three sites, are less critical for the overall interaction because other parts of the DBD also contact MED25 to form a broader interface. Based on the spacing of the sites on MED25 ACID, one DBD molecule could only interact with one MED25 site at a time. Yet, the presence of additional binding sites suggests that all three MED25 sites collectively contribute to the macroscopic DBD-MED25 interaction.
We propose a multi-step kinetic model for the ETV4-MED25 interaction ( Fig. 10 ).
An important assumption supported by our findings is that the AD and DBD cannot cooccupy the same MED25 site due to steric clash. The predominant pathway for complex formation would involve the AD of ETV4 first binding to Site 1 on MED25. The DBD of the bound ETV4 would then interact with MED25 at either Site 2 or Site 3 and could toggle between alternately binding to either of these two MED25 sites. The predominant pathway for dissociation will be limited by the slower release of the DBD. In this scheme, the AD and DBD of ETV4 and three MED25 ACID sites combine to form a high-affinity and multivalent interaction.
Interestingly, JUN/FOS factors also use a multivalent mechanism for interacting with MED25. FOS strongly interacts with MED25 by binding to Site 1, like ETV4 AD.
JUN weakly interacts with MED25 by itself, but binds to MED25 Sites 2 and 3 when FOS is also present. Therefore, the multiple binding sites on MED25 provide a route for combinatorial interaction from a single transcription factor and may allow for cooperative recruitment of MED25 by multiple factors, an idea further explored below.
Autoinhibition and regulation of ETV4
The conserved ETS domain results in similar DNA-binding properties for most ETS transcription factors [60] . However, evidence clearly indicates that individual ETS factors have distinct biological roles [61] ; how is such specificity achieved? Part of this specificity can be ascribed to the diverse flanking inhibitory regions that are specific to individual subfamilies of ETS factors. In the ETS1 and ETV1/4/5 subfamilies, both inhibitory α -helices that pack against the ETS domain and intrinsically disordered sequences contribute to autoinhibition [54, 62] . The subfamily-specific α -helices also provide unique scaffolds for intermolecular interactions. In addition to MED25, USF1
relieves the DNA-binding autoinhibition of ETV4 [63] , whereas, RUNX1 and PAX5 counter ETS1 autoinhibition [64, 65] . RUNX1 interacts with the ETS domain and flanking α -helices that are specific to ETS1 and ETS2 and blocks interaction between the disordered inhibitory region and the DNA-binding domain [66] . This DNA-binding activation in ETS1 is likely the reason that ETS1 specifically regulates ETS-RUNX composite DNA recognition sites in T-cells [67] . Here, we have demonstrated that MED25 interacts with the ETS domain and with H4, an inhibitory helix specific to the ETV1/4/5 subfamily. MED25 interaction with H4 relieves autoinhibition from H4 but does not appear to disturb inhibition from the disordered N-terminal inhibitory domain.
Interestingly, acetylation of lysines relieves the inhibition from this disordered domain [54] . MED25 also interacts with CBP, a protein acetyltransferase [50] . Therefore, a hypothetical ETV4-MED25-CBP complex could maximally activate ETV4 DNA binding by relieving autoinhibition from both inhibitory domains and warrants further investigation. In conclusion, the ETV4-MED25 interaction is an example of how distinct flanking inhibitory sequences can set up specific protein partnerships that regulate the DNA-binding activity of a particular ETS factor.
Multivalent AD-cofactor interactions
The multivalency of MED25 ACID with at least three distinct ETV4 binding sites could enable cooperative recruitment of MED25 to target genes. In PC3 cells, MED25
occupies genomic regions that were enriched for ETS and AP1 DNA-binding sequences.
Thus, cooperative MED25 recruitment could be accomplished through interactions with AP1 and ETV4. We propose that FOS and ETV4 could simultaneously contact MED25 based on differences in binding modes; the strong interaction with FOS would occupy MED25 Site 1 while ETV4 DBD would bind to Sites 2 or 3 (Fig. S11 ). Many genomic regions have ETS and AP1 DNA-binding sites in close proximity that would allow for this concurrent interaction [57] . Such a combinatorial interaction could also explain the retained function of ETV1/4/5 truncations in prostate cancer that lack the N-terminal AD [31, 32] ; the tighter binding FOS would outcompete ETV4 AD for interaction with MED25 Site 1, making the AD of ETV4 dispensable for the recruitment of MED25 to composite ETS-AP1 DNA sequences. The presence of multiple interaction sites on MED25
suggests that multiple transcription factors may cooperatively recruit MED25 to target genes.
In addition to the ETS factors and JUN/FOS described here, ATF6α, CBP, HNF4α, RARα, and SOX9 also interact with MED25 [43, 50, 51, 53] . ATF6α, CBP, and SOX9, bind to the ACID domain, though detailed structural and biochemical studies describing their binding sites have not been performed. Our genomic investigation did not suggest a broad role for these factors in recruiting MED25 in PC3 cells. However, given the plasticity of MED25 ACID binding sites used by ETV4, other ACID-binding factors may also be able to recruit MED25, along with ETV4, at select regions or in different cell types. The nuclear receptors (NRs), HNF4α and RARα, bind to MED25 through a NR box located outside of the ACID domain, which is thus distinct from Sites 1-3 described here. Therefore, cooperative recruitment of MED25 could be accomplished through simultaneous interaction with a nuclear receptor and any one of the ACID-interacting transcription factors. In particular, cooperative MED25 recruitment by ETV1/4/5 and androgen receptor (AR) could be an important mechanism for the oncogenic role of these transcription factors in prostate cancer; transcriptional coregulation by ETS and AR has been previously described [29, [68] [69] [70] , although the potential importance of MED25 recruitment was not investigated. domains of CBP by binding to opposite faces of these domains [21] . The p53 ADs also interact with at least two other CBP domains [24] , so the tetrameric form of p53 has been predicted to form a highly multivalent interaction with full-length CBP. RAD4, RAD34, and TFIIE utilize bivalency to strongly bind to the PHD domain of the general transcription factor TFIIH [22, 23] . The GCN4-MED11 interaction may be most reminiscent of MED25 and ETV4; two GCN4 ADs interact with three different activatorbinding domains in MED11 [20] .
Thus, ETV4-MED25 interactions described here extend the emerging picture of multivalent interactions between transcription factors and transcriptional coactivators in the assemblage of transcriptional machinery. Multiple interacting surfaces enables the generation of higher-affinity and specific interactions while only a single binding site mediates lower affinity interactions; the avidity between the transcription factor and the cofactor can be altered by modulating the number of potential interacting surfaces on each protein. In the case of oncogenic proteins, such as ETV4 as well as related factors ETV1 and ETV5, this understanding of multivalent interactions may enable a multipronged approach for therapeutic strategies.
Materials and Methods
Protein Expression & Purification
The genes encoding full-length ETS factors and truncated ETV4 fragments were cloned into the pET28 (Novagen) bacterial expression vector using sequence and ligation independent cloning (SLIC) [71] . ETV4 337-436 that was used as a ligand in biolayer interferometry was cloned into a custom-made vector, described below. Plasmid of human MED25 cDNA was ordered from GE Dharmacon. The gene encoding MED25 ACID (residues 391-553) was cloned into pET28 to enable protein production for NMR spectroscopy, and into a custom-made vector to express ligand protein for biolayer interferometry. This vector was based on a pGEX backbone with N-terminal GST, Avitag, and HIS 6 tags separated by thrombin and TEV cleavage sites, and followed by a For example, the full-length ETV4-MED25 interaction results in a K D of 5 ± 1 nM using the 1:1 binding model and K D values of 7 ± 3 and 28 ± 7 using the 2:1 binding models.
Agreement was similar for other ETV4 fragments and ETS factors. Therefore, the use of either model supports the conclusions that ETV1/4/5 subfamily factors bind MED25 more tightly than other ETS factors and that full-length ETV4 binds more tightly to MED25 than the AD or DBD alone. All constants were averaged separately from replicate experiments, therefore the reported K D value may not exactly equal k d / k a .
Mean and standard deviation of K D , k a , and k d values from at least three independent experimental replicates are displayed in figures and tables. from previous work for MED25 ACID [9, 73] and ETV4 337-436 [54] . NMR data were processed and analyzed using Vnmr (Varian) and Sparky (UCSF) [74] . Chemical shift perturbations (Δδ = [(Δδ H ) 2 + (0.2Δδ N ) 2 ] ½ ) and relative peak intensities for ETV4 and MED25, respectively, that were above the median and in the top ten percent for chemical shift perturbations, or below the median and in the lowest ten percent for relative peak intensities, were colored onto the structures of ETV4 (PDB: 4UUV) [56] or MED25 (PDB: 2KY6) [9] using Pymol (v1.7.0.5 enhanced for Mac, Schrödinger).
NMR Spectroscopy
Electrophoretic Mobility Shift Assays (EMSAs)
DNA 
Protein Docking
Modeling for ETV4 AD-and DBD-MED25 ACID interactions were performed using the ZDOCK server (http://zdock.umassmed.edu) [55] . PDB files 4UUV [56] and 2KY6 [9] were used as inputs for ETV4 DBD and MED25 ACID, respectively. An α -helix with the sequence "LSHFQETWLAEA" was generated using Pymol and used as the input for ETV4 AD based on the conserved sequence in ETV5 becoming more helical when interacting with MED25 ACID [7] . From our mutational data, we selected ETV4 residues Phe60 and Trp64, and Phe428 and Trp432 to be involved in the interactions between AD-MED25 ACID and DBD-MED25 ACID, respectively. We did not select any ETV4 residues to be blocked from the interface. Our NMR data showed broad perturbations of residues on multiple faces of MED25 ACID by both ETV4 AD and DBD; therefore, we did not select any MED25 residues to be involved, nor to be blocked, in these predicted interactions.
Statistical Analysis
An unpaired Mann-Whitney test was used to calculate p values using Graph Pad Prism (v.6). Values less than 0.05 were considered significant and are indicated by "*";
whereas, values greater than 0.05 were not considered significant and are indicated by brackets without an asterisk. Replicate numbers are indicated by the number of dots in each bar graph, and are included in Tables S1, S2, and S6.
Cell culture and viral expression
PC3 cells were obtained from American Type Culture Collection and cultured accordingly. Full-length MED25 cDNA was cloned into pQCXIH (Clontech) with an added C-terminal 3x FLAG tag. Oligonucleotide sequences for MED25 shRNA hairpin design are as follows, with targeting sequences in lower case:
MED25a_fwd-CCGGtgattgagggtacggccaaTTCAAGAGAttggccgtaccctcaatcacaTTTTTG
MED25a_rev-AATTCAAAAAtgtgattgagggtacggccaaTCTCTTGAAttggccgtaccctcaatca
MED25b_fwd-CCGGtcaaaggcctctaccgcatTTCAAGAGAatgcggtagaggcctttgagaTTTTTG
MED25b_rev-AATTCAAAAAtctcaaaggcctctaccgcatTCTCTTGAAatgcggtagaggcctttga MED25 shRNA hairpins were cloned into the pLKO.1 lentiviral expression vector [75] , and expression and infection of lentivirus performed following standard protocol. ETV4
shRNA retroviral constructs were previously described, and retrovirus production and infections were carried out following previously published methodology [76] . Whole-cell extracts from cells expressing control shRNA constructs, ETV4 shRNA or MED25
shRNA were run on SDS-PAGE gels and blotted to nitrocellulose membranes following standard procedures. Antibodies used for immunodetection were ETV4, ARP32262
(Aviva Systems Biology); MED25, ARP50699_P050 (Aviva Systems Biology); and beta-Tubulin, sc-55529 (Santa Cruz).
Chromatin Immunoprecipitation (ChIP) and ChIPseq analysis
ChIPs were performed as described previously [67] , with the following modifications. Cross-linked chromatin was sheared with a Branson sonifier and magnetic beads were washed with buffer containing 500 mM LiCl. Antibodies used for ChIP were:
MED25, anti-Flag M2, (Sigma Life Sciences); ETV4, ARP32262 (Aviva Systems Biology). ChIPseq libraries were prepared using the NEBNext® ChIP-Seq Library Prep
Master Mix Set for Illumina (NEB, E6240) and run on a Hiseq2000 sequencer. Two ETV4 and two MED25 ChIPseq libraries were generated from biological replicates and analyzed as replicates with one input control library. Sequence reads were aligned with Bowtie [77] to human genome HG19 and enriched regions (peaks) determined using the Useq analysis package [78] , at an FDR of 1% and Log2ratio of 2 with input DNA library used as control sample and either ETV4 or MED25 aligned reads as treatment sample.
Shared regions between ETV4 and MED25 enriched regions were defined using
IntersectRegion in Useq package with no gap. Heatmaps of shared regions were generated with DeepTools [79] using a bedfile corresponding to coordinates from the MED25-ETV4 shared regions from MED25 dataset, and bigwig files generated from the aligned ETV4, MED25 and input ChIPseq reads for one replicate. Data were aligned using the center point of this shared peak bedfile for all three maps. Enriched regions were also visualized graphically using IGV [80] .
Overrepresented DNA sequences present in the ETV4 and MED25 enriched regions were determined using the MEME-ChIP program [81] (http://meme-suite.org) using default settings except for following parameters for MEME-1) any number of repetitions for site distribution; and 2) maximum site width of 13. The central 100 bp of the ETV4 and MED25 enriched regions were interrogated by MEME-ChIP to find centrally located binding sites within the regions. We used these tighter peak coordinates with IntersectRegions to generate a more stringent set of shared ETV4-MED25 regions resulting in 611 shared regions to interrogate with MEME-ChIP. A set of size-matched random regions for comparison to the 611 ETV4 and MED25 shared regions was generated using the shuffle command in bedtools (http://bedtools.readthedocs.io/en/latest/). The 611 shared regions and 611 randomly generated regions were searched for the occurrences of C(A/C)GGAA using the FIMO program from MEME suite [82] . Only the association and dissociation phases of the sensorgram are shown. ERG (500 nM) and ETV6 (500 nM) were also tested but showed no detectable association; each ETS factor was tested twice. (c) Equilibrium dissociation constants (K D ) for the interaction between MED25 ACID and SPDEF, ETV1, and ETV4. Two K D values, denoted K D (1) and K D (2) with K D (1) being the higher-affinity interaction, are reported as these interactions better fit a 2:1 (ETS:MED25) binding model (Fig. S1c ). K D values were determined using a group fit with six different concentrations of each ETS factor ( Fig.1a and Fig. S1a,b ). Circles and squares represent the K D determined from a single, sixconcentration experiment. Horizontal lines represent the mean and standard deviation for three to five replicate experiments. K D , k a , and k d values for these interactions are summarized in Table S1 . "*" Indicates p < 0.05 in a Mann-Whitney U test. (Table S1 ). (d) K D values for the interactions between fragments of ETV4 and MED25 ACID. Filled circles and squares represent the K D value from a single experiment with six different concentrations of ETV4, and the horizontal lines represent the mean and standard deviation for three to five replicate experiments. "*" Indicates p < 0.05. Note that there are two K D values for ETV4 165-484 and ETV4 337-436 as these sensorgrams were better fit by a 2:1 (ETV4:MED25) model. In contrast, there is a single K D value for ETV4 and ETV4 as these sensorgrams were better fit by a 1:1 model. ETV4 data are included from Fig. 1c for reference. Fig. 3 . A similar motif in ETV4 AD and DBD is critical for binding to MED25. (a) Changes to the 15 N-HSQC of ETV4 DBD upon addition of unlabeled MED25 ACID at a 1:1.2 molar ratio are colored onto the structure of ETV4 DBD bound to DNA (PDB: 4UUV) [56] . Amide chemical shift perturbations (Δδ = [(Δδ H ) 2 + (0.2Δδ N ) 2 ] ½ ) that were greater than the mean are colored orange and those that were in the highest ten percent are colored in red. The peak for the amide of Glu425 is also colored red as this peak was broadened to baseline. DNA (light blue) is shown for illustrative purposes, although it was not included in the NMR experiment. See Fig. S4 for NMR spectra and quantification. (b) Fold-differences of K D values for interaction with MED25 are mapped onto the DBD of ETV4. Indicated residues were mutated to alanine in full-length ETV4, and interaction with MED25 was compared to wild type ETV4. See Fig. S3 for example sensorgrams and quantification of ETV4 mutants. (c) Structure of H4, left, and model of AD, right, in cartoon representation with side chains shown in stick representation. Note that the AD is intrinsically disordered, but takes on partial helical character when interacting with MED25 [7] ; this helical model for the AD was generated by swapping AD amino acids onto the structure of H4. α -helices and β -strands are abbreviated H and S, respectively, and numbered according to progression from N-to C-termini of the domain. (b) MED25 ACID oriented as in (a) but with surface representation and changes to the 15 N-HSQC of MED25 ACID upon addition of unlabeled ETV4 AD indicated by color. Upon addition of 0.2 molar equivalents of ETV4 AD, MED25 amide relative peak intensities that were less than the mean are colored teal and those that were in the lowest ten percent are colored blue. (c) MED25 ACID as in (b) with changes to the 15 N-HSQC upon addition of unlabeled ETV4 DBD indicated by color. Upon addition of 0.2 molar equivalents of ETV4 DBD, MED25 amide relative peak intensities that were less than the mean are colored orange and those that were in the lowest ten percent are colored in red. Sites of clustered changes upon titration of AD and/or DBD are indicated by dotted lines and arbitrarily named site one, two, or three. See Fig. S5 for 15 N-HSQC spectra of MED25 ACID alone and with unlabeled ETV4 AD or ETV4 DBD. Fig. 6 . Broad surfaces on multiple MED25 sites contribute to DBD binding. MED25 ACID represented as in Fig. 5b and with point mutants that perturb ETV4 binding colored onto the structure. Blue scale (a) and red scale (b) indicate mutations that disrupted the interaction with ETV4 AD and DBD, respectively. Fold inhibition of binding was calculated by comparing to a wild type MED25 control with AD or DBD. See Table S2 for summary of all K D values, and Fig. S7 for examples of sensorgrams with MED25 mutants. Fig. 7 . Modeling suggests multiple potential MED25 binding sites for ETV4 DBD. (a) The top ten predictions for the interaction between MED25 ACID and ETV4 AD using the ZDOCK protein-docking program [55] . MED25 ACID is represented as in Fig. 5b , ETV4 AD is displayed as a blue α -helix in cartoon representation with the side chains for Phe60 and Trp64 shown in green. AD residues Phe60 and Trp64 and MED25 residue Gln451 were selected as residues involved in the binding site for the prediction. (b) The top-ten predictions for the interaction between MED25 ACID and ETV4 DBD. The DBD was binding to MED25 Site 1 in two predictions, Site 2 in seven predictions, and Site 3 in one prediction. Modeling and representation were performed as in (a). The entire DBD is shown in cartoon format in red, and Phe428 and Phe432 side chains are displayed in green. DBD residues Phe428 and Phe432 were selected as residues involved in the binding site for the prediction. [81] . The MEME, expect-value, E, is 1 x 10 -21 . Percentages of peaks with match to motif are shown to right with comparison to randomly generated size-matched peak set in parentheses. (d) qPCR quantification of MED25-FLAG and ETV4 enrichment at putative regulatory elements for genes shown; input values displayed for comparison. Two to three independent biological replicates provided similar patterns, but different maximum levels of enrichment. A representative experiment is shown. (e) Relative expression values for indicated gene as determined by qPCR of total cDNA derived from ETV4 and MED25 knockdown PC3 cells. Two different shRNA constructs were used for both ETV4 and MED25 and denoted as a or b. Average values for biological triplicates are graphed with standard deviation. Relative expression of control knockdown cells is set at 1, and experimental sample values are graphed relative to control. 10 . Model for the multivalent ETV4-MED25 interaction. In the predominant pathway (top) the first step of interaction involves the activation domain (AD) binding to MED25 Site 1 due to its drastically faster association compared to the interaction between MED25 and the DNA-binding domain (DBD, bottom). The association and dissociation rate constants, k a (AD), k d (AD), k a (DBD), and k d (DBD) for the first binding steps are assumed equivalent to those measured for the isolated AD-MED25 and DBD-MED25 interactions, respectively. In the second step of the predominant pathway, the DBD of the bound ETV4 can only bind to the two MED25 sites that are not occupied by the AD (right). The ETV4-MED25 interaction would then be in equilibrium between two states with the DBD alternately occupying Sites 2 and 3 on MED25. The predominant pathway for dissociation of ETV4-MED25 will be limited by the slower release of the DBD. ETV4 DBD binding to MED25 is not predicted to be the predominant first step for the interaction for full-length ETV4 and MED25 (bottom), due to the drastically slower association rate (bottom). However, in circumstances where the AD is bound to another protein, or in oncogenic translocations of ETV4 that do not have the N-terminal AD, binding of the DBD to MED25 would still be a viable mode of interaction. The size of the arrows indicating association and dissociation between the unbound and AD-MED25 or DBD-MED25 complexes, and dissociation between the ETV4-MED25 and AD-MED25 or DBD-MED25 complexes, is representative of the measured rate constants for these steps. Other arrows are qualitatively sized based on mutational data and interpretations, and should not be considered as measured values.
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